Key result
Higher admission suPAR concentrations independently predicted all-cause mortality in patients with suspected NSTEACS (HR 1.93 per SD increase; 95% CI 1.48-2.51; P<0.0001).
Why the study?
Does soluble urokinase plasminogen activator receptor (suPAR) measurement predict all-cause mortality in patients admitted with suspected non-ST-segment elevation acute coronary syndrome?
Cohort (n=449)
No
Does soluble urokinase plasminogen activator receptor (suPAR) measurement predict all-cause mortality in patients admitted with suspected non-ST-segment elevation acute coronary syndrome?
Hazard Ratio: 1.93 (95% CI 1.48–2.51)
p-value: p=< 0.0001
suPAR is a strong, independent predictor of long-term all-cause mortality in patients admitted with suspected NSTEACS, improving risk stratification beyond traditional variables like ECG and troponin.
No takes yet. Share an insight, caveat, or question.
suPAR may refine mortality risk assessment in suspected NSTEACS; leaves open its role in guiding therapy or trials.
Lyngbæk et al. (2013) conducted a cohort in Suspected non-ST-segment elevation acute coronary syndrome (NSTEACS) (n=449). Soluble urokinase plasminogen activator receptor (suPAR) was evaluated on All-cause mortality (HR 1.93, 95% CI 1.48-2.51, p=< 0.0001). Higher admission suPAR concentrations independently predicted all-cause mortality in patients with suspected NSTEACS (HR 1.93 per SD increase; 95% CI 1.48-2.51; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: